Anticonvulsant hypersensitivity syndrome. Incidence, prevention and management

Drug Safety

Volumn 21, Issue 6, 1999, Pages 489-501

  Knowles, Sandra R ^a   Shapiro, Lori E ^a   Shear, Neil H ^a,b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMINOTRANSFERASE; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; AROMATIC COMPOUND; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CORTICOSTEROID; CREATININE; DAPSONE; GABAPENTIN; IMMUNOGLOBULIN; LAMOTRIGINE; MINOCYCLINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; POLYCYCLIC AROMATIC HYDROCARBON; SORBINIL; SULFONAMIDE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

BLOOD CELL COUNT; CENTRAL NERVOUS SYSTEM DISEASE; CREATININE BLOOD LEVEL; CROSS REACTION; DETOXIFICATION; DISEASE PREDISPOSITION; DRUG HYDROXYLATION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG WITHDRAWAL; FEVER; HUMAN; HYPOTHYROIDISM; IMMUNE RESPONSE; LABORATORY TEST; LIVER TOXICITY; LUNG TOXICITY; MALAISE; NEPHROTOXICITY; PATIENT COUNSELING; PHARYNGITIS; PRIORITY JOURNAL; RASH; REVIEW; SEIZURE; TOXIC EPIDERMAL NECROLYSIS; URINALYSIS;

EID: 0033390357     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199921060-00005     Document Type: Review

References (110)

1. 1. Vittorio C, Muglia J. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995; 155: 2285-90
2. 2. Anonymous. Case records of the Massachusetts General Hospital: weekly clinicopathological exercises. Case 26-1996: a seven-year-old boy with fever, lymphadenopathy, hepatosplenomegaly, and prominent eosinophilia. N Engl J Med 1996; 335: 577-84
3. 3. Konishi G, Naganuma Y, Hongo K, et al. Carbamazepine-induced skin rash in children with epilepsy. Eur J Pediatr 1993; 152: 605-8
4. 4. Shear N, Spielberg S. Anticonvulsant hypersensitivity syndrome, in vitro assessment of risk. J Clin Invest 1988; 82: 1826-32
5. 5. Haruda F. Phenytoin hypersensitivity: 38 cases. Neurology 1979; 29: 1480-5
6. 6. Handfield-Jones S, Jenkins R, Whittaker S, et al. The anticonvulsant hypersensitivity syndrome. Br J Dermatol 1993; 129: 175-7
7. 7. Tomsick R. The phenytoin syndrome. Cutis 1983; 32: 535-41
8. 8. Prosser T, Lander R. Phenytoin-induced hypersensitivity reactions. Clin Pharm 1987; 6: 728-34
9. 9. Rivey M, Stone J. Carbamazepine hypersensitivity reaction. Brain Inj 1991; 5: 57-62
10. 10. Parker W, Shearer C. Phenytoin hepatotoxicity: a case report and review. Neurology 1979; 29: 175-8
11. 11. Lane T, Peterson E. Hepatitis as a manifestation of phenobarbital hypersensitivity. South Med J 1984; 77: 94
12. 12. Ting S, Dunsky E. Diphenylhydantoin-induced hepatitis. Ann Allergy 1982; 48: 331-2
13. 13. Olsson R, Zettergren L. Anticonvulsant-induced liver damage. Am J Gastroenterol 1988; 83: 576-7
14. 14. Smythe M, Unstead G. Phenytoin hepatotoxicity: a review of the literature. Drug Intell Clin Pharm 1989; 23: 13-8
15. 15. Schlienger R, Shear N. Antiepileptic drug hypersensitivity syndrome. Epilepsia 1998; 39 Suppl.: S3-S7
16. 16. Merritt H, Putnam T. Sodium diphenylhydantoinate in treatment of convulsive disorders: toxic symptoms and their prevention. Arch Neurol Psychiatry 1939; 42: 1053-8
17. 17. Chaiken R, Goldberg B, Segal J. Dilantin sensitivity: report of a case of hepatitis with jaundice, pyrexia and exfoliative dermatitis. N Engl J Med 1950; 242: 897-8
18. 18. Tennis P, Stern R. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997; 49: 542-6
19. 19. Schlienger R, Oh P, Knowles S, et al. Quantifying the costs of serious adverse drug reactions to antiepileptic drugs. Epilepsia 1998; 39 Suppl.: S27-S32
20. 20. Roujeau JC, Stern R. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-85
21. 21. Spielberg S, Shear N, Hutson N, et al. In-vitro assessment of hypersensitivity syndrome associated with sorbinil. Ann Intern Med 1991; 114: 720-4
22. 22. Knowles S, Shapiro L, Shear N. Serious adverse reactions induced by minocycline: a report of 13 patients and review of the literature. Arch Dermatol 1996; 132 (8): 934-9
23. 23. Schlienger R, Knowles S, Shear N. Lamotrigine-associated anticonvulsant hypersensitivity syndrome. Neurology 1998; 51: 1172-5
24. 24. Dhar G, Pierach CA, Ahamed PN, et al. Diphenylhydantoin-induced hepatic necrosis. Postgrad Med 1974; 56: 128-34
25. 25. Mullick F, Ishak K. Hepatic injury associated with diphenylhydantoin therapy. Am J Clin Palhol 1980; 74: 442-52
26. 26. Cowan L, Bodensteiner JB, Leviton A, et al. Prevalence of the epilepsies in children and adolescents. Epilepsia 1989; 30: 94-106
27. 27. Shapiro L, Neumann M, Malkiewicz I, et al. Black race may predict increased severe cutaneous adverse reactions in patients with phenytoin hypersensitivity reactions. Clin Invest Med 1998; 21: 515
28. 28. Hyson C, Sadler M. Cross sensitivity of skin rashes with antiepileptic drugs. Can J Neurol Sci 1997; 24: 245-9
29. 29. Rapp R, Norton J, Young B, et al. Cutaneous reactions in head-injured patients receiving phenytoin for seizure prophylaxis. Neurosurgery 1983; 13: 272-5
30. 30. Wilson T, Hojer B, Tomson G, et al. High incidence of a concentration-dependent skin reaction in children treated with phenytoin. BMJ 1978; 1: 1583-6
31. 31. Chadwick D, Shaw M, Foy P, et al. Serum anticonvulsant concentrations and the risk of drug-induced skin eruptions. J Neurol Neurosurg Psychiatry 1984; 47: 642-4
32. 32. Shapiro L, Shear N. Mechanisms of drug reactions: the metabolic track. Sem Cutan Med Surg 1996; 15: 217-27
33. 33. Taliercio C, Olney B, Lie J. Myocarditis related to drug hypersensitivity. Mayo Clin Proc 1985; 60: 463-8
34. 34. Stephan W, Parks R, Tempest B. Acute hypersensitivity pneumonitis associated with carbamazepine therapy. Chest 1978; 74: 463-4
35. 35. Murphy D, Kronick J, Rieder M. Acute respiratory failure mediated by reactive drug metabolites. Biol Neonat 1995; 67: 223-9
36. 36. Kleier R, Breneman D, Boiko S. Generalized pustulation as a manifestation of the anticonvulsant hypersensitivity syndrome. Arch Dermatol 1991; 127: 1361-4
37. 37. Morkunas A, Miller M. Anticonvulsant hypersensitivity syndrome. Med Toxicol 1997; 13: 727-39
38. 38. Robbie M, Scurry J, Stevenson P. Carbamazepine-induced severe systemic hypersensitivity reaction with eosinophilia. Drug Intell Clin Pharm 1988; 22: 783-4
39. 39. Gupta A, Eggo M, Uetrecht J, et al. Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides. Clin Pharmacol Ther 1992; 51: 56-67
40. 40. Callot V, Roujeau J, Bagot M, et al. Drug-induced pseudolymphoma and hypersensitivity syndrome: two different clinical entities. Arch Dermatol 1996; 123: 1315-21
41. 41. Schreiber M, McGregor J. Pseudolymphoma syndrome. Arch Derm 1968; 97: 297-300
42. 42. Sinnige H, Boender C, Kuypers E, et al. Carbamazepine-induced pseudolymphoma and immune dysregulation. J Intern Med 1990; 227: 355-8
43. 43. Saltzstein S, Ackerman L. Lymphadenopathy induced by anticonvulsant drugs and mimicking clinically and pathologically malignant lymphomas. Cancer 1959; 12: 164-82
44. 44. Souteyrand P, d'Incan M. Drug-induced mycosis-fungoides-like lesions. Curr Probl Dermatol 1990; 19: 176-82
45. 45. Wilden J, Scott C. A pseudolymphomatous reaction in soft tissue associated with phenytoin sodium. J Clin Pathol 1978; 31: 76-1764
46. 46. Rijlaarsdam J, Scheffer E, Meijer CJ, et al. Cutaneous pseudo-T-cell lymphomas: a clinicopathologic study of 20 patients. Cancer 1992; 69: 717-24
47. 47. d'Incan M, Souteyrand P, Bignon Y, et al. Hydantoin-induced cutaneous pseudolymphoma with clinical, pathologic, and immunologic aspects of Sezary syndrome. Arch Dermatol 1992; 128: 1371-4
48. 48. Yates P, Stockdill G, McIntyre M. Hypersensitivity to carbamazepine presenting as pseudolymphoma. J Clin Pathol 1986; 39: 1224-8
49. 49. Shuttleworth D, Graham-Brown R, Williams A, et al. Pseudolymphoma associated with carbmazepine. Clin Exp Dermatol 1984; 9: 421-3
50. 50. Sigal-Nahum M, Petit A, Gaulier A, et al. A nodular cutaneous lymphoproliferative disorder during carbamazepine administration. Br J Dermatol 1992; 127: 545-7
51. 51. Rijlaarsdam U, Scheffer E, Meijer C, et al. Mycosis fungoide-like lesions associated with phenytoin and carbamazepine therapy. J Am Acad Dermatol 1991; 24: 216-20
52. 52. Wolf R, Kahane E, Sandbank M. Mycosis fungoides-like lesions associated with phenytoin therapy. Arch Dermatol 1985; 121: 1181-2
53. 53. Rosenthal C, Noguera C, Coppola A, et al. Pseudolymphoma with mycosis fungoides manifestations, hyperresponsiveness to diphenylhydantoin, and lymphocyte disregulation. Cancer 1982; 49: 2305-14
54. 54. Welykyj S, Gradini R, Nakao J, et al. Carbamazepine-induced eruption histologically mimicking mycosis fungoides. J Cutan Pathol 1990; 17: 111-6
55. 55. De Vriese A, Philippe J, Van Renterghem D, et al. Carbamazepine hypersensitivity syndrome: report of four cases and review of the literature. Medicine 1995; 74: 144-51
56. 56. Savich R, Traisman H. Phenobarbital hypersensitivity reaction. III Med J 1986; 169: 232-4
57. 57. Plantin P, Cartier H, Le Bihan G, et al. Syndrome d'hypersensibilite medicamenteuse au cours d'un traitement par acide valproique. Presse Med 1995; 24: 1624
58. 58. Schlumberger E, Chavez F, Palacios L, et al. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 1994; 35: 359-67
59. 59. Besag F, Wallace S, Dulac O, et al. Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 1995; 127: 991-7
60. 60. Jones D, Chiap V, Resor S, et al. Phenytoin-like hypersensitivity associated with lamotrigine. J Am Acad Dermatol 1997; 36: 1016-8
61. 61. Chaffin J, Davis S. Suspected lamotrigine-induced toxic epidermal necrolysis. Ann Pharmacotherapy 1997; 31: 720-3
62. 62. Makin A, Fitt S, Williams R, et al. Fulminant hepatic failure induced by lamotrigine. BMJ 1995; 311: 292
63. 63. Nicholson R, Kelly K, Grant I. Leucopenia associated with lamotrigine. BMJ 1995; 310: 504
64. 64. Sullivan J, Watson A. Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management. Aust J Dermatol 1996; 37: 208-12
65. 65. Schaub J, Williamson P, Barnes E, et al. Multisystem adverse reaction to lamotrigine [letter]. Lancet 1994; 344: 481
66. 66. Sterker M, Berrouschot J, Schneider D. Fatal course of toxic epidermal necrolysis under treatment with lamotrigine. Int J Clin Pharmacol Ther 1995; 33: 595-7
67. 67. Wadelius M, Karlsson T, Wadelius C, et al. Lamotrigine and toxic epidermal necrolysis [letter]. Lancet 1996; 348: 1041
68. 68. Page R, O'Neil M, Yarbrough D, et al. Fatal toxic epidermal necrolysis related to lamotrigine administration. Pharmacotherapy 1998; 18: 392-8
69. 69. Chattergoon D, McGuigan M, Koren G, et al. Multiorgan dysfunction and disseminated intravascular coagulopathy in children receiving lamotrigine and valproic acid. Neurology 1997; 49: 1442-4
70. 70. Mitchell P. Paediatric lamotrigine use hit by rash reports. Lancet 1997; 349: 1080
71. 71. Richens A. Safety of lamotrigine. Epilepsia 1994; 35 Suppl.: S37-40
72. 72. Yuen A, Land G, Weatherley B, et al. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992; 33: 511-3
73. 73. Spielberg S. In vitro analysis of idiosyncratic drug reactions. Clin Biochem 1986; 19: 142-4
74. 74. Houwerzijl J, DeGast G, Nater J. Patch tests in drug eruptions. Contact Dermatitis 1975; 1: 180-92
75. 75. Jones M, Fernandez-Herrera J, Dorado J, et al. Epicutaneous test in carbamazepine cutaneous reactions. Dermatology 1994; 188: 18-20
76. 76. Alanko K. Patch testing in cutaneous reactions caused by carbamazepine. Contact Dermatitis 1993; 29: 254-7
77. 77. Romaguera C, Grimalt F, Vilaplana J, et al. Erythroderma from carbamazepine. Contact Dermatitis 1989; 20: 304-5
78. 78. Scerri L, Shall L, Zaki I. Carbamazepine-induced anticonvulsant hypersensitivity syndrome - pathogenic and diagnostic considerations. Clin Exp Dermatol 1993; 18: 540-2
79. 79. Puig L, Nadal C, Fernandex-Figueras M, et al. Carbamazepine-induced drug rashes: diagnostic value of patch tests depends on clinico-pathologic presentation. Contact Dermatitis 1996; 34: 435-7
80. 80. Houwerzijl J, De Gast G, Nater J, et al. Lymphocyte-stimulation tests and patch tests in carbamazepine hypersensitivity. Clin Exp Immunol 1977; 29: 272-7
81. 81. Silva R, Machado A, Brandao M, et al. Patch test diagnosis in carbamazepine erythroderma. Contact Dermatitis 1986; 15: 254-5
82. 82. Spielberg S, Gordon G, Blake D, et al. Anticonvulsant toxicity in vitro: possible role of arene oxides. J Pharmacol Exp Ther 1981; 217: 386-9
83. 83. Riley F, Leeder S. In vitro analysis of metabolic predisposition to drug hypersensitivity reactions. Clin Exp Immunol 1995; 99: 1-6
84. 84. Wolkenstein P, Charue D, Laurent P, et al. Metabolic predisposition to cutaneous adverse drug reactions. Arch Dermatol 1995; 131: 544-51
85. 85. Spielberg S, Gordon G, Blake D, et al. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 1981; 305: 722-7
86. 86. Zanni M, von Greyerz S, Schnyder B, et al. T cell reactions in patients showing adverse immune reactions to drugs. Inflamm Res 1996; 45 Suppl.: S79-84
87. 87. Merk H, Baron J, Hertl M, et al. Lymphocyte activation in allergic reactions elicited by small molecular-weight compounds. Int Arch Allergy Immunol 1997; 113: 173-6
88. 88. Pirmohamed M, Graham A, Roberts P, et al. Carbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine. Br J Clin Pharmacol 1991; 32: 741-9
89. 89. Gleichmann H. Studies on the mechanism of drug sensitization: T-cell dependent popliteal lymph node reaction to diphenylhydantoin. Clin Immunol Immunopathol 1981; 18: 203-11
90. 90. Murphy J, Mashman J, Miller J, et al. Suppression of carbamazepine-induced rush with prednisone. Neurology 1991; 41: 144-5
91. 91. Vick N. Suppression of carbamazepine-induced skin rash with prednisone. New Engl J Med 1983; 309: 1193-4
92. 92. Smith M, Bleck T. Convulsive disorders: toxicity of anticonvulsants. Clin Neuropharmacol 1991; 14: 97-115
93. 93. Gaedigk A, Spielberg S, Grant D. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. Pharmacogenetics 1994; 4: 142-53
94. 94. Friedman P, Strickland I, Pirmohamed M, et al. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 1994; 130: 598-604
95. 95. Pirmohamed M, Kitteringham N, Breckenridge A, et al. Detection of an autoantibody directed against human liver microsomal protein in a patient with carbamazepine hypersensitivity. Br J Clin Pharmacol 1992; 33: 183-6
96. 96. Leeder J, Riley R, Cook V, et al. Human anti-cytochrome P450 antibodies in aromatic anticonvulsant-induced hyperscnsitivity reactions. J Pharmacol Exp Ther 1992; 263: 360-7
97. 97. Alldredge B, Knutsen A, Ferriero D. Antiepileptic drug hypersensitivity syndrome: in vitro and clinical observations. Pediatr Neurol 1994; 10: 169-71
98. 98. Gennis M, Vemuri R, Burns E, et al. Familial occurrence of hypersensitivity to phenytoin. Am J Med 1991; 91: 631-4
99. 99. Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 433-43
100. 100. Knowles S, Shapiro L, Shear N. Serious dermatologic reactions in children. Curr Opin Pediatr 1997; 9: 388-95
101. 101. Chopra S, Levell NJ, Cowley G, et al. Systemic corticosteroids in the phenytoin hypersensitivity syndrome. Br J Dermatol 1996; 134: 1109-12
102. 102. Sheretyz E, Jegasothy B, Lazarus G. Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis. J Am Acad Dermatol 1985; 12: 178-81
103. 103. Chaidemenos G, Chrysomallis F, Sombolos K, et al. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol 1997; 36: 218-21
104. 104. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-3
105. 105. Eames P. Adverse reactions to carbamazepine managed by desensitization. Lancet 1989; 1; 509-10
106. 106. Purves S, Hashimoto S, Tse K. Successful desensitization of patients with carbamazepine allergy [abstract]. Can J Neurol Sci 1988; 15: 237
107. 107. Smith H, Newton R. Adverse reactions to carbamazepine managed by desensitisation [letter]. Lancet 1985; 1: 753
108. 108. Watts D, Bird J. Oxcarbazepine sensitivity treated by desensitisation [letter]. BMJ 1991; 541: 376
109. 109. Zakrzewska J, Ivanyi L. In vitro lymphocyte proliferation by carbmazepine, carbamazepine-10, 11 epoxide, and oxcarbazepine in the diagnosis of drug-induced hypersensitivity. J Allergy Clin Immunol 1988; 82: 110-5
110. 110. Reents S, Luginbuhl W, Davis S. Phenytoin-carbamazepine cross-sensitivity. Ann Pharmacother 1989; 23: 235-6